1. Home
  2. BFH vs NAMS Comparison

BFH vs NAMS Comparison

Compare BFH & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bread Financial Holdings Inc.

BFH

Bread Financial Holdings Inc.

HOLD

Current Price

$85.52

Market Cap

3.3B

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$28.50

Market Cap

3.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BFH
NAMS
Founded
1996
2019
Country
United States
Netherlands
Employees
N/A
100
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3B
3.3B
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
BFH
NAMS
Price
$85.52
$28.50
Analyst Decision
Hold
Strong Buy
Analyst Count
15
8
Target Price
$80.64
$46.75
AVG Volume (30 Days)
643.6K
838.8K
Earning Date
04-23-2026
05-06-2026
Dividend Yield
1.08%
N/A
EPS Growth
98.36
N/A
EPS
4.15
N/A
Revenue
$4,521,400,000.00
N/A
Revenue This Year
$53.25
$17.96
Revenue Next Year
$3.53
$540.65
P/E Ratio
$20.53
N/A
Revenue Growth
N/A
N/A
52 Week Low
$47.87
$16.79
52 Week High
$99.13
$42.00

Technical Indicators

Market Signals
Indicator
BFH
NAMS
Relative Strength Index (RSI) 55.77 36.61
Support Level $68.65 $23.48
Resistance Level $99.13 $37.25
Average True Range (ATR) 3.27 1.69
MACD -0.60 -0.61
Stochastic Oscillator 27.88 7.88

Price Performance

Historical Comparison
BFH
NAMS

About BFH Bread Financial Holdings Inc.

Formed by a combination of JCPenney's credit card processing unit and The Limited's credit card bank business, Bread Financial is a provider of private-label and co-branded credit cards, loyalty programs, and marketing services. The company's most financially significant unit is its credit card business that partners with retailers to jointly market Bread's credit cards to their customers. The company also retains a minority interest in spun-off LoyaltyOne, which operates the largest airline miles loyalty program in Canada and offers marketing services to grocery chains in Europe and Asia.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: